Key result
First-line management of essential hypertension with diuretics had an incremental cost of GH¢ 276 ($179) per disability-adjusted life-year avoided compared with no treatment.
Why the study?
Universal healthcare coverage requires difficult resource allocation decisions, prompting capacity building in health technology assessment to inform hypertension management policy in Ghana.
What is the cost-effectiveness of different antihypertensive medicines for uncomplicated essential hypertension in Ghana?
What is the cost-effectiveness of different antihypertensive medicines for uncomplicated essential hypertension in Ghana?
Diuretics are the most cost-effective first-line treatment for uncomplicated essential hypertension in Ghana, supporting evidence-informed policy and resource allocation.
May support diuretic first-line use in essential hypertension; leaves open generalizability beyond modeled data.
OBJECTIVES: Universal healthcare coverage in low- and middle-income countries requires challenging resource allocation decisions. Health technology assessment is one important tool to support such decision making. The International Decision Support Initiative worked with the Ghanaian Ministry of Health to strengthen health technology assessment capacity building, identifying hypertension as a priority topic area for a relevant case study. METHODS: Based on guidance from a national technical working group of researchers and policy makers, an economic evaluation and budget impact analysis were undertaken for the main antihypertensive medicines used for uncomplicated, essential hypertension. The analysis aimed to address specific policy questions relevant to the National Health Insurance Scheme. RESULTS: The evaluation found that first-line management of essential hypertension with diuretics has an incremental cost per disability-adjusted life-year avoided of GH¢ 276 ($179 in 2017, 4% of gross national income per capita) compared with no treatment. Calcium channel blockers were more effective than diuretics but at a higher incremental cost: GH¢ 11 061 per disability-adjusted life-year avoided ($7189 in 2017; 160% of gross national income per capita). Diuretics provide better health outcomes at a lower cost than angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers. Budget impact analysis highlighted the potential for cost saving through enhanced price negotiation and increased use of better-value drugs. We also illustrate how savings could be reinvested to improve population health. CONCLUSIONS: Economic evaluation enabled decision makers to assess hypertension medicines in a Ghanaian context and estimate the impact of using such evidence to change policy. This study contributes to addressing challenges associated with the drive for universal healthcare coverage in the context of constrained budgets.
No takes yet. Share an insight, caveat, or question.
Gad et al. (2019) studied uncomplicated, essential hypertension. Diuretics vs. no treatment was evaluated on incremental cost per disability-adjusted life-year avoided. First-line management of essential hypertension with diuretics had an incremental cost of GH¢ 276 ($179) per disability-adjusted life-year avoided compared with no treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: